Form 4: Carisma CSO Exercises Options, Sells Shares

Carisma Therapeutics' Chief Scientific Officer, Michael Klichinsky, exercised stock options and subsequently sold 56,982 shares of common stock.

Summary

• Michael Klichinsky, Chief Scientific Officer of Carisma Therapeutics Inc. (CARM), reported a transaction on October 7, 2025.
• Klichinsky exercised 56,982 stock options at an exercise price of $0.11 per share.
• Immediately following the exercise, Klichinsky sold all 56,982 shares of common stock.
• The shares were sold at a weighted average price of $0.2542, with individual transaction prices ranging from $0.2441 to $0.2647.
• After these transactions, Klichinsky's direct beneficial ownership of common stock is 0 shares.
• The stock option was fully vested and had an expiration date of November 1, 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction for an executive to realize value from vested options, which is neither inherently positive nor negative for the company's operational outlook.

Positives

• The Chief Scientific Officer realized a profit from the exercise of vested stock options, indicating the options held value.
• The transaction demonstrates the liquidity of the company's common stock.

Negatives

• An insider selling shares, even following an option exercise, can sometimes be perceived as a neutral to slightly negative signal by some investors, as it reduces the officer's direct equity stake.

Future Outlook

This Form 4 filing, being a transactional report, does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This routine insider transaction reflects an individual executive's personal financial activity related to vested equity compensation and does not directly relate to broader industry trends or the competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale following an option exercise and is unlikely to have a significant direct impact on the company's operational performance or long-term value. It may be viewed as a minor reduction in insider ownership.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Carisma Therapeutics, CARM, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Michael Klichinsky